SCHEMBL22446321

SCHEMBL22446321

C=CC(=O)N1CCC(Oc2ccc(OC)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
TET3 O43151 2/20 0.56
FBXL19 Q6PCT2 2/20 0.56
CXXC5 Q7LFL8 2/20 0.56
TET1 Q8NFU7 2/20 0.56
KDM2B Q8NHM5 2/20 0.56
CXXC4 Q9H2H0 2/20 0.56
KDM2A Q9Y2K7 2/20 0.56
EPHX2 P34913 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 1/20 0.52
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 1/20 0.49
RYR2 Q92736 1/20 0.47
TEAD1 P28347 1/20 0.47
TEAD3 Q99594 1/20 0.47
EGFR P00533 2/20 0.47
ERBB2 P04626 1/20 0.47
GPR183 P32249 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22173964 0.96 TET3 (0.53) KMT2ATET3FBXL19CXXC5TET1
SCHEMBL22174233 0.87 TET3 (0.51) KMT2ATET3FBXL19CXXC5TET1
SCHEMBL22173975 0.86 EPHX2 (0.56) KMT2ATET3FBXL19CXXC5TET1
SCHEMBL22446341 0.85 EPHX2 (0.49) KMT2ATET3FBXL19CXXC5TET1
SCHEMBL22173988 0.85 EPHX2 (0.49) KMT2ATET3FBXL19CXXC5TET1
SCHEMBL22173950 0.85 EPHX2 (0.53) KMT2ATET3FBXL19CXXC5KDM2B
SCHEMBL27965490 0.84 SMN1; SMN2 (0.57) KMT2AEPHX2SMN1; SMN2MAPTGAA
SCHEMBL22196904 0.83 JAK3 (0.52) EPHX2TEAD1TEAD3BTK
SCHEMBL22174118 0.83 EPHX2 (0.58) EPHX2TEAD1TEAD3EGFRBTK
SCHEMBL22174156 0.83 PARP10 (0.61) KMT2ARAB9AALDH1A1TEAD1TEAD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771689-B2 Cereblon modulators and uses thereof VIVIDION THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2022-09-22 US disclosed
US-10781239-B2 In vivo engineered cereblon protein VIVIDION THERAPEUTICS, INC. (US) 2020-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885TET3 666/4885FBXL19 247/4885
US-11771689-B2 Cereblon modulators and uses thereof CRBN, CBFB, CNN2 KMT2A 3580/4885TET3 4521/4885FBXL19 3394/4885
US-10781239-B2 In vivo engineered cereblon protein CRBN, CDR2, DCUN1D4 KMT2A 607/4885TET3 666/4885FBXL19 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.